Dr Vishnu Vasudevan (@vvdevandr) header
Dr Vishnu Vasudevan (@vvdevandr) profile picture

Endocrinologist

Kerala, India
Joined September 2012
Photo by Dr Vishnu Vasudevan (@vvdevandr)Photo by Dr Vishnu Vasudevan (@vvdevandr)Photo by Dr Vishnu Vasudevan (@vvdevandr)Photo by Dr Vishnu Vasudevan (@vvdevandr)Photo by Dr Vishnu Vasudevan (@vvdevandr)Photo by Dr Vishnu Vasudevan (@vvdevandr)
I’m an endocrinologist who sees 50-60 patients a day in Kerala. Most of what patients believe about GLP-1 drugs, thyroid disease, and weight loss is wrong — not because they’re careless, but because the information reaching them is.
3
3
3
139
26,847
Dr Vishnu Vasudevan retweeted
I am proud to see AIIMS New Delhi achieve an important milestone in fetal medicine by performing India’s first open fetal surgery to repair spina bifida. More than 30 clinicians and nurses came together to give an unborn baby a better chance at life. My congratulations to the entire team.
India’s first fetal surgery to repair a baby’s spine before birth was performed at AIIMS Neurosciences Centre. Led by Prof. Deepak Gupta, with Prof. Neena Malhotra, Prof. Vimi Rewari, Prof. Mihir Pandia, Dr. K Aparna Sharma, Dr. Rashmi Ramachandran, Dr. Gyanendra Pal Singh, Dr. Shashank Chauhan, Dr. Ramesh Agarwal, Dr. Deepika Kainth - in total, a team of over 30 clinicians and nurses. Fetal surgery can help selected babies, but prevention remains key. #SpinaBifida #FolicAcid #MaternalHealth #FetalMedicine #AIIMSNewDelhi
9
38
1
270
12,112
Dr Vishnu Vasudevan retweeted
The Indian Medical Association (IMA) has written to the Union Information and Broadcasting Ministry to urgently review the promotional content of Sunny Deol-starrer Suryaa – Ant Se Aarambh Tak, alleging that it generalises corruption in the medical profession and depicts violence against healthcare workers in ways that could erode public trust and put doctors’ safety at risk. #IMA #DoctorsSafety #HealthcareWorkers #MedicalProfession #SunnyDeol #Suryaa #PublicTrust #Healthcare #india
16
34
3
140
7,860
Interesting one from clinic this week: a tirzepatide patient reporting intense meat cravings — not sugar, not carbs — right before her next dose. End-of-dose hunger rebound is well known (t½ ~5 days). Craving specificity like this isn’t. Anecdote, not evidence. Anyone else seeing this? @IndiaESI
2
2
1,021
Dr Sanjay Kalra @SanjayKalraDr1 — my Manasa Guru, Ex-President, Endocrine Society of India 🇮🇳 @IndiaESI , mentor to so many of us — did something rare. He shared his own 6-month journey on tirzepatide, as both physician and patient. 110kg → 20kg down. Here’s what he learned 🧵
3
2
18
4,689
Tip 6: Don’t self-adjust your dose especially women. Just like diet and exercise, GLP-1 dosing needs balance — not aggression.
1
3
457
But the part that stayed with me most wasn’t clinical. Dr Kalra’s closing appeal: stop judging people living with obesity. They did not choose this disease. Avoid hurtful labels, insensitive jokes — use respectful, person-first language.
7
440
Less intramuscular fat likely means better insulin sensitivity too. Strength is usually preserved in trials. Function — how well you actually move — is where the real risk sits, especially in older or frail patients.
1
60
The fix: → Protein 1-1.2g/kg/day → Resistance training 2-3x/week → Monitor lean mass AND function, not weight alone Muscle today. Independence tomorrow. #GLP1 #Tirzepatide #Endocrinology #DiabesityCare
54
Every week, multiple DMs like this: “Took my 2nd dose of Mounjaro. Weight stuck for 2 weeks. What do I do?” The pattern is always the same — patients started on GLP-1/GIP therapy without proper pre-treatment counseling. Plateaus in the first weeks are expected, not a treatment failure. Dose titration takes months, not days. This isn’t a patient education gap. It’s a prescribing practice gap. @IndiaESI @deepduttaendo @idrlakshmi @DrVanishriG @endo
2
8
730
But Lilly has stated on record: they don’t condone this, have no data on its risk/benefit, and flag contamination risk from using devices beyond intended design — these formulations are preservative-free.
1
1
67
And that’s the real gap: no RSSDI, no Endocrine Society of India position exists on multi-dose pen duration or microdosing. We’re each setting our own rules right now.
1
66
Fellow GLP-1 prescribers — what’s your in-use cutoff, and why? Would genuinely value real practice patterns here, not just theory. #Tirzepatide #GLP1 #EndocrinologyIndia
1
75
The rationale isn’t nothing though. Cost. Tolerability. Some patients get real appetite suppression at a fraction of standard dose. I use lower doses selectively in my own practice.
1
1
79
Every tirzepatide RCT started dosing at 2.5mg. Nothing lower has ever been studied. Microdosing from a multi-dose pen is off-label, full stop — however sound the rationale sounds.
1
110